Physix FrontierPhysix Frontier · News Briefing Card (enbrief · Nov 9, 2026)
ByteDance spins off AI drug unit Anew Labs, raising $290M
KEY FACTS
- ByteDance fully spun off its in-house AI drug discovery business in June, forming a new company called Anew Labs.
- Anew Labs closed a $290 million first funding round in September at a post-money valuation of about $1.5 billion.
- ByteDance retains a 56% stake in Anew Labs and continues to control the company.
- Anew Labs' most advanced pipeline is an IL-17 small molecule, still in the preclinical lead optimization stage.
- BioMap was reported in March of this year to have confidentially filed with the Hong Kong Stock Exchange.
KEY DATA
$290 millionAnew Labs first-round funding
about $1.5 billionAnew Labs post-money valuation
56%ByteDance stake
about 60%Share of sector funding taken by China's four largest 2026 rounds
PHYSIX OBSERVATION
By spinning off its AI drug team wholesale while keeping a controlling stake, a big tech company is effectively using outside capital to price its internal pipeline, pushing both risk and valuation outward at the same time. The notable signal: projects commanding high valuations are still stuck in preclinical, meaning capital is betting on models and teams, not clinical data. Domestic money is accelerating toward the leaders, and the funding window for smaller players is narrowing.
Source: enbrief original report ↗